We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.
- Authors
Fisher, B; Dignam, J; Bryant, J; Wolmark, N
- Abstract
Previously reported information from B-14, a National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized, placebo-controlled clinical trial, demonstrated that patients with estrogen receptor (ER)-positive breast cancer and negative axillary lymph nodes experienced a prolonged benefit from 5 years of tamoxifen therapy. When these women were rerandomized to receive either placebo or more prolonged tamoxifen therapy, they obtained no additional advantage from tamoxifen through 4 years of follow-up. Because the optimal duration of tamoxifen administration continues to be controversial and because there have been 3 more years of follow-up and a substantial increase in the number of events since our last report, an update of the B-14 study is appropriate.
- Publication
Journal of the National Cancer Institute, 2001, Vol 93, Issue 9, p684
- ISSN
0027-8874
- Publication type
Journal Article
- DOI
10.1093/jnci/93.9.684